ArticleFrontiers in immunology2022

Case Report: First-Line Immunotherapy for Esophageal Squamous Carcinoma Combined With Hypopharyngeal Squamous Carcinoma Yields Sustained Survival Benefit.

Yi Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.